{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:12:09Z","timestamp":1792613529613,"version":"4.5.0"},"reference-count":9,"publisher":"Cambridge University Press (CUP)","issue":"S2","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Laryngol. Otol."],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the management of thyroid cancer in adults and is based on the 2014 British Thyroid Association guidelines.<\/jats:p><jats:sec id=\"S0022215116000578_sec_a1\"><jats:title>Recommendations<\/jats:title><jats:p>\u2022 Ultrasound scanning (USS) of the nodule or goitre is a crucial investigation in guiding the need for fine needle aspiration cytology (FNAC). (R)<\/jats:p><jats:p>\u2022 FNAC should be considered for all nodules with suspicious ultrasound features (U3\u2013U5). If a nodule is smaller than 10 mm in diameter, USS guided FNAC is not recommended unless clinically suspicious lymph nodes on USS are also present. (R)<\/jats:p><jats:p>\u2022 Cytological analysis and categorisation should be reported according to the current British Thyroid Association Guidance. (R)<\/jats:p><jats:p>\u2022 Ultrasound scanning assessment of cervical nodes should be done in FNAC-proven cancer. (R)<\/jats:p><jats:p>\u2022 Magnetic resonance imaging (MRI) or computed tomography (CT) should be done in suspected cases of retrosternal extension, fixed tumours (local invasion with or without vocal cord paralysis) or when haemoptysis is reported. When CT with contrast is used pre-operatively, there should be a two-month delay between the use of iodinated contrast media and subsequent radioactive iodine (I<jats:sup>131<\/jats:sup>) therapy. (R)<\/jats:p><jats:p>\u2022 Fluoro-deoxy-glucose positron emission tomography imaging is not recommended for routine evaluation. (G)<\/jats:p><jats:p>\u2022 In patients with thyroid cancer, assessment of extrathyroidal extension and lymph node disease in the central and lateral neck compartments should be undertaken pre-operatively by USS and cross-sectional imaging (CT or MRI) if indicated. (R)<\/jats:p><jats:p>\u2022 For patients with Thy 3f or Thy 4 FNAC a diagnostic hemithyroidectomy is recommended. (R)<\/jats:p><jats:p>\u2022 Total thyroidectomy is recommended for patients with tumours greater than 4 cm in diameter or tumours of any size in association with any of the following characteristics: multifocal disease, bilateral disease, extrathyroidal spread (pT3 and pT4a), familial disease and those with clinically or radiologically involved nodes and\/or distant metastases. (R)<\/jats:p><jats:p>\u2022 Subtotal thyroidectomy should not be used in the management of thyroid cancer. (G)<\/jats:p><jats:p>\u2022 Central compartment neck dissection is not routinely recommended for patients with papillary thyroid cancer without clinical or radiological evidence of lymph node involvement, provided they meet all of the following criteria: classical type papillary thyroid cancer, patient less than 45 years old, unifocal tumour, less than 4 cm, no extrathyroidal extension on ultrasound. (R)<\/jats:p><jats:p>\u2022 Patients with metastases in the lateral compartment should undergo therapeutic lateral and central compartment neck dissection. (R)<\/jats:p><jats:p>\u2022 Patients with follicular cancer with greater than 4 cm tumours should be treated with total thyroidectomy. (R)<\/jats:p><jats:p>\u2022 I<jats:sup>131<\/jats:sup> ablation should be carried out only in centres with appropriate facilities. (R)<\/jats:p><jats:p>\u2022 Serum thyroglobulin (Tg) should be checked in all post-operative patients with differentiated thyroid cancer (DTC), but not sooner than six weeks after surgery. (R)<\/jats:p><jats:p>\u2022 Patients who have undergone total or near total thyroidectomy should be started on levothyroxine 2 \u00b5g per kg or liothyronine 20 mcg tds after surgery. (R)<\/jats:p><jats:p>\u2022 The majority of patients with a tumour more than 1 cm in diameter, who have undergone total or near-total thyroidectomy, should have I<jats:sup>131<\/jats:sup> ablation. (R)<\/jats:p><jats:p>\u2022 A post-ablation scan should be performed 3\u201310 days after I<jats:sup>131<\/jats:sup> ablation. (R)<\/jats:p><jats:p>\u2022 Post-therapy dynamic risk stratification at 9\u201312 months is used to guide further management. (G)<\/jats:p><jats:p>\u2022 Potentially resectable recurrent or persistent disease should be managed with surgery whenever possible. (R)<\/jats:p><jats:p>\u2022 Distant metastases and sites not amenable to surgery which are iodine avid should be treated with I<jats:sup>131<\/jats:sup> therapy. (R)<\/jats:p><jats:p>\u2022 Long-term follow-up for patients with differentiated thyroid cancer (DTC) is recommended. (G)<\/jats:p><jats:p>\u2022 Follow-up should be based on clinical examination, serum Tg and thyroid-stimulating hormone assessments. (R)<\/jats:p><jats:p>\u2022 Patients with suspected medullary thyroid cancer (MTC) should be investigated with calcitonin and carcino-embryonic antigen levels (CEA), 24 hour catecholamine and nor metanephrine urine estimation (or plasma free nor metanephrine estimation), serum calcium and parathyroid hormone. (R)<\/jats:p><jats:p>\u2022 Relevant imaging studies are advisable to guide the extent of surgery. (R)<\/jats:p><jats:p>\u2022 RET (Proto-oncogene tyrosine-protein kinase receptor) proto-oncogene analysis should be performed after surgery. (R)<\/jats:p><jats:p>\u2022 All patients with known or suspected MTC should have serum calcitonin and biochemical screening for phaeochromocytoma pre-operatively. (R)<\/jats:p><jats:p>\u2022 All patients with proven MTC greater than 5 mm should undergo total thyroidectomy and central compartment neck dissection. (R)<\/jats:p><jats:p>\u2022 Patients with MTC with lateral nodal involvement should undergo selective neck dissection (IIa\u2013Vb). (R)<\/jats:p><jats:p>\u2022 Patients with MTC with central node metastases should undergo ipsilateral prophylactic lateral node dissection. (R)<\/jats:p><jats:p>\u2022 Prophylactic thyroidectomy should be offered to RET-positive family members. (R)<\/jats:p><jats:p>\u2022 All patients with proven MTC should have genetic screening. (R)<\/jats:p><jats:p>\u2022 Radiotherapy may be useful in controlling local symptoms in patients with inoperable disease. (R)<\/jats:p><jats:p>\u2022 Chemotherapy with tyrosine kinase inhibitors may help in controlling local symptoms. (R)<\/jats:p><jats:p>\u2022 For individuals with anaplastic thyroid carcinoma, initial assessment should focus on identifying the small proportion of patients with localised disease and good performance status, which may benefit from surgical resection and other adjuvant therapies. (G)<\/jats:p><jats:p>\u2022 The surgical intent should be gross tumour resection and not merely an attempt at debulking. (G)<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0022215116000578","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T10:37:06Z","timestamp":1463049426000},"page":"S150-S160","source":"Crossref","is-referenced-by-count":211,"title":["Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines"],"prefix":"10.1017","volume":"130","author":[{"given":"A L","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Scott-Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Perros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"S0022215116000578_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-013-1152-8"},{"key":"S0022215116000578_ref1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12515"},{"key":"S0022215116000578_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-013-1157-3"},{"key":"S0022215116000578_ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000354537"},{"key":"S0022215116000578_ref9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0302"},{"key":"S0022215116000578_ref3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0460"},{"key":"S0022215116000578_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-013-1139-5"},{"key":"S0022215116000578_ref8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335"},{"key":"S0022215116000578_ref2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"}],"container-title":["The Journal of Laryngology &amp; Otology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0022215116000578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T19:39:03Z","timestamp":1555702743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0022215116000578\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":9,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0022215116000578"],"URL":"https:\/\/doi.org\/10.1017\/s0022215116000578","relation":{},"ISSN":["0022-2151","1748-5460"],"issn-type":[{"value":"0022-2151","type":"print"},{"value":"1748-5460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}